Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Cerebrospinal Fluid

Cerebrospinal Fluid

Cerebrospinal fluid (CSF) is a colorless liquid that flows around the brain and the spinal cord, playing a vital role in the protection, support, and overall function of the central nervous system (CNS). CSF production, circulation, and absorption are tightly regulated processes essential for the brain and spinal cord to function properly.
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Advances in therapy·2021

Same author

COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Multiple sclerosis and related disorders·2021

Same author

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2021

Same author

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Multiple sclerosis and related disorders·2021

Same author

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.

Journal of neuroimmunology·2021

Same author

Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective.

Multiple sclerosis and related disorders·2021

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

Multiple sclerosis cerebrospinal fluid biomarkers.

Gavin Giovannoni¹

¹Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK. G.Giovannoni@ion.ucl.ac.uk

Disease Markers

|November 25, 2006

Summary

Standardizing cerebrospinal fluid (CSF) collection and analysis is crucial for multiple sclerosis (MS) biomarker research. Currently, no CSF biomarker is suitable as a surrogate endpoint for MS progression.

Area of Science:

Neurology
Biomarker Research
Cerebrospinal Fluid Analysis

Background:

Cerebrospinal fluid (CSF) is vital for studying multiple sclerosis (MS) pathology.
Standardization of CSF sampling and assay validation is essential for reliable biomarker research.
Current candidate biomarkers lack the suitability to serve as surrogate endpoints in MS clinical trials.

Purpose of the Study:

To highlight the critical need for standardized methodologies in CSF biomarker research for multiple sclerosis.
To emphasize the requirements for validating biomarkers as surrogate endpoints.
To discuss the advantages of bulk biomarkers over intermittent inflammatory markers in MS.

Main Methods:

Review of current practices in CSF collection, processing, and storage for MS biomarker studies.

More Related Videos

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

Related Experiment Videos

Last Updated: Jul 18, 2026

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

Discussion of assay validation requirements for biomarker detection.

Analysis of criteria for establishing surrogate endpoints and reporting standards for MS research.

Main Results:

Several factors require standardization for CSF biomarker research in MS, including collection parameters, processing, storage, and temporal relation to disease activity.
Assay validation is necessary to enhance study power.
No current candidate biomarker meets the criteria for a surrogate endpoint in MS.

Conclusions:

Standardized protocols for CSF collection, processing, and analysis are imperative for advancing MS biomarker research.
Formal methods and consensus criteria are needed to establish reliable surrogate endpoints.
Bulk biomarkers like glial fibrillary acidic protein (GFAP) and neurofilaments (NF) show promise for tracking neurodegeneration in MS.